These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
686 related items for PubMed ID: 15482514
1. Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren. Roost HP, Gassner M, Grize L, Wüthrich B, Sennhauser FH, Varonier HS, Zimmermann H, Braun-Fahrländer Ch, SCARPOL-team. Pediatr Allergy Immunol; 2004 Oct; 15(5):401-7. PubMed ID: 15482514 [Abstract] [Full Text] [Related]
3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K, Nicoara C, Germann D, Matter L. Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837 [Abstract] [Full Text] [Related]
4. No epidemiological evidence for infant vaccinations to cause allergic disease. Koppen S, de Groot R, Neijens HJ, Nagelkerke N, van Eden W, Rümke HC. Vaccine; 2004 Sep 03; 22(25-26):3375-85. PubMed ID: 15308362 [Abstract] [Full Text] [Related]
6. Allergic disease and atopic sensitization in children in relation to measles vaccination and measles infection. Rosenlund H, Bergström A, Alm JS, Swartz J, Scheynius A, van Hage M, Johansen K, Brunekreef B, von Mutius E, Ege MJ, Riedler J, Braun-Fahrländer C, Waser M, Pershagen G, PARSIFAL Study Group. Pediatrics; 2009 Mar 03; 123(3):771-8. PubMed ID: 19255001 [Abstract] [Full Text] [Related]
8. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T, Baer M, Willems P. Pediatr Infect Dis J; 2007 Feb 03; 26(2):153-8. PubMed ID: 17259879 [Abstract] [Full Text] [Related]
10. Why do parents hesitate to vaccinate their children against measles, mumps and rubella? Alfredsson R, Svensson E, Trollfors B, Borres MP. Acta Paediatr; 2004 Sep 03; 93(9):1232-7. PubMed ID: 15384890 [Abstract] [Full Text] [Related]
11. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. Olesen AB, Juul S, Thestrup-Pedersen K. Acta Derm Venereol; 2003 Sep 03; 83(6):445-50. PubMed ID: 14690341 [Abstract] [Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P. Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835 [Abstract] [Full Text] [Related]
19. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P. Vaccine; 2009 May 05; 27(20):2701-6. PubMed ID: 19428882 [Abstract] [Full Text] [Related]